Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Doximity, Inc. (DOCS) SEC filings page provides access to the company’s official regulatory disclosures as a New York Stock Exchange–listed issuer. Doximity files annual, quarterly, and current reports that describe its financial condition, results of operations, governance matters, and material events affecting the business.
In its filings and related press releases, Doximity presents condensed consolidated balance sheets, statements of operations, and statements of cash flows, along with discussions of non-GAAP financial measures. The company explains how it calculates metrics such as non-GAAP gross profit, non-GAAP net income, adjusted EBITDA, and free cash flow, and provides reconciliations to GAAP results. These documents allow readers to see how Doximity evaluates its performance beyond standard accounting measures.
Current reports on Form 8-K for DOCS include items such as quarterly earnings announcements, changes in executive roles, annual meeting voting results, and legal developments. For example, Doximity has filed 8-Ks to furnish earnings press releases, to report the outcomes of its annual meeting of stockholders, to disclose changes in its general counsel and related roles, and to describe a securities litigation settlement agreement that remains subject to court approval and other customary conditions.
Through its proxy materials and related filings, Doximity also reports on corporate governance topics, including the election of directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation. Voting results, including the participation of Class A and Class B common stock, are detailed in these documents.
On this page, AI-powered tools can summarize lengthy DOCS filings, highlight key sections on revenue trends, profitability, cash flows, and risk disclosures, and surface notable items such as settlement agreements or executive transitions. Users can quickly review quarterly reports, annual reports, and Form 4 and other transaction-related filings, while relying on real-time updates from the SEC’s EDGAR system to follow new disclosures from Doximity, Inc.
Doximity, Inc. (DOCS) reported an insider transaction by a director on 11/21/2025. The director converted 10,000 shares of Class B Common Stock into Class A Common Stock and then sold 10,000 shares of Class A Common Stock at $50 per share.
The filing notes that the sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, the director directly owned 3,221 shares of Class A Common Stock and held 333,500 derivative securities, including stock options originally granted on September 2, 2020.
A shareholder of DOCS has filed a Form 144 notice to sell up to 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an aggregate market value of $500,000, and the filing notes that 137,373,858 shares of common stock are outstanding.
The 10,000 shares to be sold were acquired on 11/21/2025 via a stock option exercise from the issuer, paid in cash on the same date. Over the prior three months, the same seller, Timothy Cabral, reported sales of 20,000 shares of common stock on 09/24/2025 for gross proceeds of $1,500,000 and 6,360 shares on 09/02/2025 for gross proceeds of $421,655.28.
Doximity, Inc. (DOCS) reported a routine insider equity transaction by its Chief Financial Officer on a Form 4. On 11/15/2025, 5,121 shares of Class A common stock were withheld at a price of $49.62 per share to cover tax withholding obligations tied to the vesting of previously granted restricted stock units. After this tax-related withholding, the officer beneficially owns 364,672 shares of Class A common stock directly. The filing specifies that the share withholding followed an issuer election made in advance and does not represent a discretionary trade or open-market sale by the reporting person.
Doximity, Inc. reported an insider tax-withholding transaction by its Chief Executive Officer. On 11/15/2025, the CEO, who is also a director and 10% owner, had 8,005 shares of Class A Common Stock withheld by Doximity at a price of $49.62 per share. This withholding was done to cover tax obligations arising from the vesting of previously granted restricted stock units and was executed under a standing election by the company, rather than as a discretionary open-market trade by the executive. Following this transaction, the reporting person beneficially owned 2,241,053 shares of Doximity Class A Common Stock in direct ownership.
Doximity, Inc. (DOCS) director reported receiving 31,064 restricted stock units (RSUs) on November 15, 2025 under the company’s 2021 Stock Option and Incentive Plan. The RSUs vest in 10 equal quarterly installments after that date, contingent on the director’s continued service with the company at each vesting date. Each RSU converts into one share of Doximity Class A common stock at settlement, awarded at a stated price of $0 per share. Following this grant, the director beneficially owns 50,903 shares of Doximity Class A common stock in total.
Doximity, Inc. (DOCS) reported insider activity by its Chief Financial Officer. On 11/04/2025, the officer acquired 20,200 and 2,668 shares of Class A common stock, each labeled as a code C conversion from Class B following option exercises. The option exercises were at $4.12 and $2.21 per share, respectively.
Following these transactions, the officer beneficially owned 369,793 shares of Class A common stock, held directly. Footnotes state Class B shares are convertible into Class A on a one-for-one basis at the holder’s option, with automatic conversion upon certain events. The reported stock options carry expirations on 12/21/2030 and 09/28/2030, with vesting schedules as disclosed.
Doximity, Inc. reported strong quarterly performance. Revenue for the quarter ended September 30, 2025 reached $168.5 million, up from $136.8 million a year ago. Net income was $62.1 million versus $44.2 million, and diluted EPS was $0.31 compared to $0.22. Gross profit rose to $152.1 million while operating income increased to $63.7 million.
Operating cash flow for the six months was $156.0 million. The company ended the quarter with $169.2 million in cash and cash equivalents and $709.1 million in marketable securities. Doximity repurchased and retired 4,496,467 Class A shares for $220.2 million since program inception, with $279.8 million remaining authorized. The company completed the $36.3 million Pathway Medical acquisition, adding $18.7 million of developed technology and $17.0 million of goodwill.
Doximity, Inc. filed an 8-K announcing it issued a press release with financial results for its fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except as expressly referenced. The report was signed by Chief Financial Officer Anna Bryson.
Doximity (DOCS): Director Form 4 filing. On 11/03/2025, the reporting person exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, converted those 2,000 Class B shares into 2,000 Class A shares, and sold 2,000 Class A shares at $66.44 per share pursuant to a Rule 10b5-1 trading plan adopted on November 12, 2024. Following these transactions, Class A Common Stock beneficially owned directly totaled 19,839 shares. The stock option was originally granted on June 10, 2020 and vests in 36 equal monthly installments starting March 27, 2020, with an expiration date of June 9, 2030.
FMR LLC filed Amendment No. 4 to Schedule 13G reporting beneficial ownership of 8,777,627.56 shares of Doximity (DOCS) Class A common stock, representing 6.4%, with a date of event of 09/30/2025.
FMR reports sole voting power over 8,765,947.45 shares and sole dispositive power over 8,777,627.56 shares. Abigail P. Johnson reports sole dispositive power over 8,777,627.56 shares and no voting power. The filing certifies the holdings were acquired and are held in the ordinary course and not to change or influence control.